Compounds of formula iv: ##STR1## wherein R and R2 are hydrogen or methyl; wherein R1 is --COOH, --COOR' in which R' is alkyl of 1 to 3 carbon atoms, inclusive, --(CnH2 n)A in which n is an integer of 1 to 3 and A is fluoro, chloro, bromo, trifluoromethyl, hydroxy, alkoxy, in which the alkyl group is defined as above, or ##STR2## in which R" and R'" are hydrogen or alkyl as defined above or together ##STR3## is pyrrolidino, piperidino, morpholino, 4-methylpiperazino, 4-(2-hydroxyethyl)-piperazino; wherein R3 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, or nitro; and wherein Ar is phenyl, o-chlorophenyl, o-fluorophenyl, 2,6-difluorophenyl, or 2-pyridyl, are produced.
The compounds of formula iv of this invention are sedatives, tranquilizers and muscle-relaxants and can be used for such purposes in mammals and birds.
|
1. A compound of formula iv: ##STR17## wherein R and R2 are hydrogen or methyl; wherein R1 is --COOH, --COOR' in which R' is alkyl or 1 to 3 carbon atoms (inclusive), --(CH2)n A in which n is an integer of 1 to 3 and A is fluoro, chloro, bromo, trifluoromethyl, hydroxy, alkoxy in which the alkyl group is defined as above, or ##STR18## in which R" and R'" are hydrogen or alkyl as defined above or together ##STR19## is pyrrolidino, piperidino, morpholino, 4-methylpiperazino, 4-(2-hydroxyethyl)piperazino; wherein R3 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, or nitro, and wherein Ar is phenyl, o-chlorophenyl, o-fluorophenyl, 2,6-difluorophenyl, or 2-pyridyl, and the pharmacologically acceptable acid addition salts thereof.
16. A process for the production of a compound iva: ##STR23## wherein R and R2 are hydrogen or methyl; wherein R'1 is --COOH, COOR' in which R' is alkyl of 1 to 3 carbon atoms (inclusive), --(CH2)n A' in which A' is fluoro, chloro, bromo, trifluoromethyl, hydroxy, alkoxy in which the alkyl group is defined as above, which comprises: treating between -20° to 80°C a compound of the formula I: ##STR24## wherein R2, R3, and Ar are defined as above with a compound of the formula ii: ##STR25## wherein R'1 and R are defined as above and Y is chlorine, bromine, iodine, or --O--SO2 R4 (R4 is alkyl of 1-3 carbon atoms, phenyl, or tolyl) in an inert organic solvent, to give the compound III: ##STR26## wherein Ar, R, R'1, R2, R3, and Y are defined as above; and allowing to cyclize III at a temperature between 10° to 60° C., to obtain the corresponding compound of formula iva.
2. A compound according to
3. A compound according to
4. A compound according to
5. A compound according to
6. A compound according to
7. A compound according to
8. A compound according to
9. A compound according to
10. A compound according to
11. A compound according to
12. A compound according to
13. A compound according to
14. A compound according to
15. A compound according to
17. The process of
18. The process of
19. The process of
|
This invention is concerned with new organic compounds and more particularly with triazinobenzodiazepines and methods for the production thereof.
The new products of this invention and the process of production thereof can be illustratively represented by the following formulae: ##STR4## If R1 is --(CH2)n A' (A' is X and X is chloro or bromo) and ##STR5## wherein R and R2 are hydrogen or methyl; wherein R1 is --COOH; COOR', in which R' is alkyl of 1 to 3 carbon atoms, inclusive, --(CnH2 n)A in which A is fluoro, chloro, bromo, hydroxy, or alkoxy in which the alkyl group is defined as above; wherein R3 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, or nitro, and wherein Ar is phenyl, o-chlorophenyl, o-fluorophenyl, 2,6-difluorophenyl, or 2-pyridyl, and wherein X is chlorine or bromine, and wherein Y is chloro, bromo, iodo, or --O--SO2 R4 (R4 is alkyl of 1-3 carbon atoms, phenyl, or tolyl) and wherein R" and R'" are hydrogen or alkyl defined as above or together ##STR6## is pyrrolidino, piperidino, morpholino, 4-methylpiperazino, or 4-(2-hydroxymethyl)piperazino.
The invention therefore comprises compounds of formula IV ##STR7## wherein R and R2 are hydrogen or methyl; wherein R1 is --COOH, COOR' in which R' is alkyl of 1 to 3 carbon atoms, inclusive, --(CnH2 n)A in which n is an integer of 1 to 3 and A is fluoro, chloro, bromo, hydroxy, alkoxy in which the alkyl group is defined as above, or ##STR8## in which R" and R'" are hydrogen or alkyl as defined above or together ##STR9## is pyrrolidino, piperidino, morpholino, 4-methylpiperazino, or 4-(2-hydroxyethyl)-piperazino; wherein R3 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, or nitro, and wherein Ar is phenyl, o-chlorophenyl, o-fluorophenyl, 2,6-difluorophenyl, or 2-pyridyl.
The invention also encompasses besides the compounds of formula IV, the pharmacologically acceptable acid addition salts of these compounds.
The more desirable products of this invention have the formula IVA ##STR10## wherein A' is hydroxy or ##STR11## in which Ro and R'o are hydrogen or alkyl of 1 to 3 carbon atoms, inclusive; wherein n is an integer of 1 to 3; wherein R'3 is hydrogen, chloro, fluoro, or trifluoromethyl; wherein R4 is hydrogen, chloro, or fluoro; and wherein R5 is hydrogen or fluoro with the proviso that R5 is not fluoro if R4 is chloro, and the pharmacologically acceptable acid addition salts thereof.
The most desirable compounds of this invention are of the formula IVB ##STR12## wherein A" is hydroxy or dimethylamino, R"3 and R4 are hydrogen, chloro, or fluoro, and the pharmacologically acceptable acid addition salts thereof.
The process of the present invention comprises: treating a compound of formula I with a reagent of formula II to give the corresponding 2-(substituted-hydrazino)benzodiazepine III; and heating III to cyclize it and to provide the corresponding final product IV. If, as final product, a compound is desired wherein A is ##STR13## a compound wherein R1 is --(CnH2 n)X in which n is 1 to 3 and X is chloro or bromo can be reacted with a selected secondary amine in conventional manner.
Alkyl groups of 1 to 3 carbon atoms, inclusive, are exemplified by methyl, ethyl, or propyl.
The novel compounds of the formula IV and pharmacologically acceptable addition salts thereof have sedative, hypnotic, anticonvulsant, tranquilizing and muscle relaxant effects in mammals and birds. Also as feed additives they increase growth rate and feed efficiency of livestock and poultry.
The pharmacologically acceptable acid addition salts of compounds of formula IV contemplated in this invention, are the hydrochlorides, hydrobromides, hydriodides, sulfates, phosphates, cyclohexanesulfamates, methanesulfonates, maleates, citrates, and the like, prepared by reacting a compound of formula IV with the selected pharmacologically acceptable acid.
Sedative effects of compounds of formula IV are shown by the following tests in mice:
Chimney test: [Med. Exp. 4, 145 (1961)] : The test determines the ability of mice to back up and out of a vertical glass cylinder within 30 seconds. At the effective dosage, 50% of the mice failed doing it.
Dish test: Mice in Petri dishes (10 cm. diameter, 5 cm. high, partially embedded in wood shavings), climb out in a very short time, when not treated. Mice remaining in the dish for more than 3 minutes indicates tranquilization. ED50 equals the dose of test compound at which 50% of the mice remain in the dish.
Pedestal test: The untreated mouse leaves the pedestal in less than a minute to climb back to the floor of the standard mouse box. Tranquilized mice will stay on the pedestal for more than 1 minute.
Nicotine antagonism test: Mice in a group of 6 are injected with the test compound. Thirty minutes later the mice including control (untreated) mice are injected with nicotine salicylate (2 mg./kg). The control mice show overstimulation, i.e., (1) running convulsions followed by (2) tonic extensor fits; followed by (3) death. The intraperitoneal dosage of the test compound which protects 50% of the mice against (2) and (3) is the ED50.
Antagonism to strychnine (as sulfate): The test consists in orally administering into groups of 6 mice the test compound, and 30 minutes later 3 mg./kg. strychnine sulfate intraperitoneally. The survivors after 4 hours reflect the activity of the compound as a muscle relaxant and antispasmodic. A dosage of 3 mg./kg. of strychnine sulfate is routinely fatal to all the control mice. A dosage which protects 50% of the mice from death is the ED50.
The pharmaceutical forms contemplated by this invention include pharmaceutical compositions suited for oral, parenteral, and rectal use, e.g., tablets, powder packets, cachets, dragees, capsules, solutions, suspensions, sterile injectable forms, suppositories, bougies, and the like. Suitable diluents or carriers such as carbohydrates (lactose), proteins, lipids, calcium phosphate, cornstarch, stearic acid, methylcellulose and the like may be used as carriers or for coating purposes. Oil, e.g., coconut oil, sesame oil, safflower oil, cottonseed oil, peanut oil may be used for preparing solutions or suspensions of the active drug. Sweetening, coloring, and flavoring agents may be added.
For mammals and birds, food premixes, with starch, oatmeal, dried fishmeat, fishmeal, flour, and the like can be prepared.
As tranquilizer the compounds of formula IV and its pharmacologically acid addition salts can be used in dosages of 0.05-2.0 mg./kg., preferably 0.1 to 1.0 mg./kg. in oral or injectable preparations as described above, to alleviate tension and anxiety in mammals, or birds, such as e.g. occurs when animals are in travel.
Other acid addition salts of the compounds of formula IV can be made such as the fluosilicic acid addition salts which are useful mothproofing compounds or the trichloroacetates useful as herbicies against Johnson grass, Bermuda grass, yellow foxtail and green foxtail, and quack grass.
The starting compounds of formula I of this invention are synthesized as shown by Meguro et al., Tetrahedron Letters 4039 (1970).
The reactants of formula II are to a large extent commercially available, or can be made as shown by Catch et al., J. Chem. Soc., 1948, 278; Yu-hua et al., J. Gen. Chem. (USSR) 29, 3263 (1959); Arbuzov et al., J. Gen. Chem. (USSR) 32, 36-4 (1962); Magidson, et al., J. Gen. Chem (USSR) 29, 2803 (1959); Rodionov et al., Zhur. Obshahes Khim., 23, 1830 (1953); Bergman et al., J. Chem. Soc. 1958, 2259; Borowitz et al., J. Org. Chem., 34, 2687 (1969); Newberger et al., J. Chem. Soc. 1954, 1820.
In carrying out the process of this invention a selected compound I, dissolved in an inert organic solvent, is treated with a compound of formula II. Solvents useful in this reaction are tetrahydrofuran, dioxane, glyme, diglyme, ethanol, methanol, benzene, toluene, methylene, chloride, chloroform and the like. Temperatures for this reaction are between -20° to 80°C, preferably about room temperature (20° to 25°C). Temperatures above the melting point of the solvent should be used. The reactant II is used in a quantity of equimolecular to equimolecular +50% in relation to the starting benzodiazepine I. After the reaction is terminated the product III is recovered and purified in conventional manner e.g. evaporation of the mixture, extraction redissolving and filtering the impure product III, chromatography, and crystallization.
Product III is cyclized in a solvent preferably in tetrahydrofuran, but toluene, benzene, glyme, and diglyme can be used, at a temperature between 20° to 200°C, preferably between 25° to 125° C. Tetrahydrofuran is preferred since the product IVa formed under reflux conditions (about 65°C) separates from the mixture as an acid addition salt and can be recovered by filtration. Compound IV is purified in conventional manner by chromatography and crystallization.
If other solvents are employed for the cyclization (for example, ethanol or methanol) compound IVa is obtained by conventional evaporation or conversion to the free base and extraction procedures and purified as above.
Compound IVa can also be obtained by increasing the pot temperature of the first step reaction, which will provide directly from compound I compound IVa without isolation of compound III.
If a compound of formula IVc is desired, a compound of formula IVb in which R1 is --(CnH2 n)X n is 1 to 3; X is chlorine or bromine) is treated with a secondary amine of the formula ##STR14## in conventional manner.
Alternatively compounds of formula IVb (where CnH2 nX is CH2 Br) can be obtained by the bromination of compounds IVb (where CnH2 nX is CH3) using, for example, N-bromosuccinimide.
Alternatively compounds of formula IVc (where CnH2 n is R--CH--CH2 -- (R is H or CH3) can be obtained by the Mannich Reaction, for example by treating a compound of formula IVa (R1 is methyl or ethyl) with ##STR15## Other Mannich reagents ##STR16## can be used (see Organic Reactions Vol. I, Page 303 and Vol. VII, page 99) .
The following examples are illustrative of the processes and products of the present invention, but are not to be construed as limiting.
PAC 7-Chloro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-phenyl-3H-1,4 -benzodiazepineA solution of 4.7 g. (0.0165 mole) of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 83 ml. of tetrahydrofuran, under nitrogen, was cooled to 0°C and a solution of 3.1 g. (0.025 mole) of 1,3-dichloropropanone-2 in 30 ml. of tetrahydrofuran was added dropwise during 40 minutes with stirring, and the solution was allowed to warm to room temperature. After 3.5 hours, thin layer chromatography of the reaction mixture (SiO2, 10% methanol 90% chloroform) showed one spot moving much faster than the starting material. The solution was evaporated nearly to dryness in vacuo below room temperature, dissolved in 180 ml. of methylene chloride, filtered, concentrated to 90 ml., and diluted to 180 ml. with methanol. After cooling in the refrigerator, the crystals were collected, washed with methanol and dried, giving 2.10 g. of nearly white solid. Concentration of the filtrate below 20%, addition of more methanol to keep the volume at about 100 ml., and standing in the refrigerator gives 2.47 g. more product with identical infrared spectrum. The total yield was 4.57 g. (64.5%) of 7-chloro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-phenyl-3H-1, 4-benzodiazepine.
Anal. calcd. for C18 H15 Cl3 N4 : C, 54.91; H, 3.84; Cl, 27.01; N, 14.23. Found: C, 54.66; H, 3.90; Cl, 27.07; N, 14.33.
PAC 7-Chloro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-(o-chlorophen yl)-3H-1,4-benzodiazepineA solution of 3.19 g. (0.01 mole) of 7-chloro-5-o-chlorophenyl)-2-hydrazino-3H-1,4-benzodiazepine in 150 ml. of tetrahydrofuran, under nitrogen was cooled to 0°C and 1.4 g. (0.011 mole) of 1,3L -dichloropropanone in 15 ml. of tetrahydrofuran was added dropwise with stirring. After stirring at 0°C for 1/2 hour and at room temperature for 1.5 hours thin layer chromatography (SiO2, 10% methanol/90% chloroform) showed essentially one spot, Rf 7.4 as expected for the desired product, (starting material has Rf 2.4). The solution was evaporated in vacuo below 25°C giving light brown gum which solidified on trituration with ether to give 7-chloro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-(o-chlorophe nyl)-3H-1,4-benzodiazepine.
PAC 2-[[2-Chloro-1-(chloromethyl)ethylidene]-hydrazino]-5-(o-chlorophenyl)-3H-1 ,4-benzodiazepineIn the manner given in Example 1, 2-hydrazino-5-(o-chlorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1,3-dichloropropanone under nitrogen to give 2-[[2-chloro-1-(chloromethyl)ethylidene]-hydrazino]-5-(o-chlorophenyl)-3H- 1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-bromo-1-(bromomethyl)ethylidene]hydrazino]-5-(o-fluorophenyl )-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-(o-fluorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1,3-dibromopropanone under nitrogen to give 7-chloro-2-[[2-bromo-1-(bromomethyl)ethylidene]hydrazino]-5-(o-fluoropheny l)-3H-1,4-benzodiazepine.
PAC 7-Bromo-2-[[2-bromo-1-(chloromethyl)ethylidene]hydrazino]-5-(2-pyridyl)-3H- 1,4-benzodiazepineIn the manner given in Example 1, 7-bromo-2-hydrazino-5-(2-pyridyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1 -bromo-3-chloro-propanone under nitrogen to give 7-bromo-2-[[2-bromo-1-(chloromethyl)ethylidene]hydrazino]-5-(2-pyridyl)-3H -1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1, 4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-3-hydroxypropanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1 ,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-chlorophe nyl)-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-(o-chlorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-3-hydroxypropanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-chloroph enyl)-3H-1,4-benzodiazepine.
PAC 2-[[2-Bromo-1-(hydroxymethyl)ethylidene]-hydrazino]-5-(o-chlorophenyl)-3H-1 ,4-benzodiazepineIn the manner given in Example 1, 2-hydrazino-5-(o-chlorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-bromo-3-hydroxypropanone under nitrogen to give 2-[[2-bromo-1-(hydroxymethyl)ethylidene]-hydrazino]-5-(o-chlorophenyl)-3H- 1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-fluorophe nyl)-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-(o-fluorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-3-hydroxypropanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-fluoroph enyl)-3H-1,4-benzodiazepine.
PAC 7-Bromo-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1,4 -benzodiazepineIn the manner given in Example 1, 7-bromo-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-3-hydroxypropanone under nitrogen to give 7-bromo-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1, 4-benzodiazepine.
PAC 7-Chloro-2-[[2-bromo-1-(trifluoromethyl)ethylidene]hydrazino]-5-phenyl-3H-1 ,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1,1,1-trifluoro-3-bromopropanone under nitrogen to give 7-chloro-2-[[2-bromo-1-(trifluoromethyl)ethylidene]hydrazino]-5-phenyl-3H- 1,4-benzodiazepine.
PAC 7-Nitro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1,4 -benzodiazepineIn the manner given in Example 1, 7-nitro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-3-hydroxypropanone under nitrogen to give 7-nitro-2[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1,4 -benzodiazepine.
PAC 7-(Trifluoromethyl)-2-[[2-bromo-1-(hydroxymethyl)ethylidene]hydrazino]-5-ph enyl-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-(trifluoromethyl)-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-bromo-3-hydroxypropanone under nitrogen to give 7-(trifluoromethyl)-2-[[2-bromo-1-(hydroxymethyl)ethylidene]hydrazino]-5-p henyl-3H-1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(2-hydroxy-2-methylpropyl)ethylidene]hydrazino]-5-p henyl-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-bromo-4-hydroxy-4-methyl-2-pentanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(2-hydroxy-2-methylpropyl)ethylidene]hydrazino]-5- phenyl-3H-1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(3-chloropropyl)ethylidene]hydrazino]-5-(o-chloroph enyl)-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-(o-chlorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1,5-dichloro-2-pentanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(3-chloropropyl)ethylidene]hydrazino]-5-(o-chlorop henyl)-3H-1,4-benzodiazepine.
PAC 7-Fluoro-2-[[2-bromo-1-(ethoxymethyl)ethylidene]hydrazino]-5-(o-fluoropheny l)-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-fluoro-2-hydrazino-5-(o-fluorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-3-ethoxypropanone under nitrogen to give 7-fluoro-2-[[2-bromo-1-(ethoxymethyl)ethylidene]hydrazino]-5-(o-fluorophen yl)- 3H-1,4-benzodiazepine.
PAC 7-Nitro-2-[[2-bromo-1-(2-carbethoxyethyl)ethylidene]hydrazino]-5-phenyl-3H- 1,4-benzodiazepineIn the manner given in Example 1, 7-nitro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with ethyl 5-chloro-4-oxopentanoate under nitrogen to give 7-nitro-2-[[2-bromo-1-(carbethoxyethyl)ethylidene]hydrazino]-5-phenyl-3H-1 ,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(fluoromethyl)ethylidene]hydrazino]-5-(o-chlorophen yl)-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-(o-chlorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-3-fluoropropanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(fluoromethyl)ethylidene]hydrazino]-5-(o-chlorophe nyl)-3H-1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-hydroxy-1-(3-carbomethoxypropyl)ethylidene]hydrazino]-5-phen yl-3H-1,4-benzodiazepine, methanesulfonate esterIn the manner given in Example 1, 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 5-carbomethoxy-2-oxopentyl methanesulfonate under nitrogen to give 7-chloro-2-[[2-hydroxy-1-(3-carbomethoxypropyl)ethylidene]hydrazino] -5-phenyl-3H-1,4-benzodiazepine, methanesulfonate ester.
PAC 7-Fluoro-2-[[2-chloro-1-(hydroxymethyl)propylidene]hydrazino]-5-phenyl-3H-1 ,4-benzodiazepineIn the manner given in Example 1, 7-fluoro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 3-chloro-1-hydroxy-2-butanone under nitrogen to give 7-fluoro-2-[[2-chloro-1-(hydroxymethyl)propylidene]hydrazino]-5-phenyl-3H- 1,4-benzodiazepine.
PAC 7-(Trifluoromethyl)-2-[[2-chloro-1-(chloroethyl)ethylidene]hydrazino]-5-phe nyl-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-(trifluoromethyl)-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1,4-dichloro-2-butanone under nitrogen to give 7-(trifluoromethyl)-2-[[2-chloro-1-(2-chloroethyl)ethylidene]hydrazino]-5- phenyl-3H-1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(4-hydroxybutyl)ethylidene]hydrazino]-5-(2,6-difluo rophenyl)-3H-1,4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-(2,6-difluorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1-chloro-6-hydroxy-2-hexanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(4-hydroxybutyl)ethylidene]hydrazino]-5-(2,6-diflu oropheny1)-3H-1,4-benzodiazepine.
PAC 7-Chloro-2-[[2-chloro-1-(2-chloroethyl)ethylidene]hydrazino]-5-phenyl-3H-1, 4-benzodiazepineIn the manner given in Example 1, 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 1,4-dichloro-2-butanone under nitrogen to give 7-chloro-2-[[2-chloro-1-(2-chloroethyl)ethylidene]hydrazino]-5-phenyl-3H-1 ,4-benzodiazepine.
PAC 9-Chloro-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzo diazepine hydrochlorideA solution of 5.7 g. (0.02 mole) of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 100 ml. of tetrahydrofuran under nitrogen was cooled to 0°C and a solution of 2.8 g. (0.022 mole) of 1,3-dichloropropanone-2 in 25 ml. of tetrahydrofuran was added dropwise during 15 minutes. The solution was allowed to warm to room temperature and remain at room temperature for 14 days. After concentration to 100 ml., the resulting solid was collected giving 4.66 g. of tan solid. This was recrystallized from methanol, with treatment with activated charcoal (Darco G-60), yielding 3.3 g. (44%) of 9-chloro-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine hydrochloride of melting point 215°-260°C with decomposition and darkening from 218°C up.
Anal. calcd. for C18 H14 Cl2 N4. HCl: C, 54.91; H, 3.84; Cl, 27.01; N, 14.23. Found: C, 54.61; H, 3.92; Cl, 27.13; N, 14.17.
A solution of 0.394 g. (0.001 mole) of 7-chloro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-phenyl-3H-1, 4-benzodiazepine in 20 ml. of tetrahydrofuran under nitrogen, was stirred at room temperature for 7 days. The resulting precipitate was collected, washed with tetrahydrofuran and dried, yielding 0.08 g. (20.3%) of a tan solid. Ir was same as for the analyzed sample of 9-chloro-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine hydrochloride.
PAC 9-Chloro-2-(chloromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a] [1,4]benzodiazepine hydrochlorideA solution of 7-chloro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-(o-chlorophe nyl)-3H-1,4-benzodiazepine, prepared in situ in tetrahydrofuran as in Example 2 from 3.19 g. (0.01 mole) of 7-chloro-5-(o-chlorophenyl)-2-hydrazino-3H-1,4-benzodiazepine, was stirred under reflux in a nitrogen atmosphere for 3 hours during which time the solvent is allowed to boil off to concentrate the solution to 75 ml. After standing at room temperature overnight the resulting crystalline hydrochloride was collected washed with tetrahydrofuran and dried giving 1.54 g. (36%) of tan solid. This was dissolved in methanol, treated at the boiling point with activated charcoal, filtered, concentrated to 27 ml. and cooled yielding 0.65 g. of 9-chloro-2-(chloromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine hydrochloride of melting point 230°-240° C. (dec.).
Anal. calcd. for C18 H13 Cl3 N4. HCl: C, 50.50; H, 3.36; Cl, 33.12; N, 13.09. Found: C, 50.57; H, 3.24; Cl, 33.05; N, 13.04.
The hydrochloric acid addition salt can be treated in water with aqueous sodium bicarbonate solution until neutral, and the free base extracted with methylene chloride. Evaporation of the methylene chloride solution gives 9-chloro-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine.
PAC 2-(Chloromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]benz odiazepine and its hydrochlorideIn the manner given in Example 24, 2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-(o-chlorophenyl)-3H-1 ,4-benzodiazepine in tetrahydrofuran can be stirred to give 2-(chloromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]ben zodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(bromomethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a][ 1,4]benzodiazepine and its hydrobromideIn the manner given in Example 25, 7-chloro-2-[[2-bromo-1-(bromomethyl)ethylidene]hydrazino]-5-(o-fluoropheny l)-3H-1,4-benzodiazepine in tetrahydrofuran can be refluxed to give 9-chloro-2-(bromomethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a] [1,4]benzodiazepine as the hydrobromide. The free base can be obtained as described in Example 25.
PAC 9-Bromo-2-(chloromethyl)-1,5-dihydro-7-(2-pyridyl)-as-triazino[ 4,3-a][1,4]benzodiazepine and its hydrochlorideIn the manner given in Example 24, 7-bromo-2-[[2-bromo-1-(chloromethyl)ethylidene]hydrazino]-5-(2-pyridyl)-3H -1,4-benzodiazepine in tetrahydrofuran can be stirred to give 9-bromo-2-(chloromethyl)-1,5-dihydro-7-(2-pyridyl)-as-triazino[4,3-a][1,4 ]benzodiazepine as the hydrobromide. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine and its hydrochlorideIn the manner given in Example 24, 7-chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1 ,4-benzodiazepine in tetrahydrofuran can be stirred to give 9-chloro-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]ben zodiazepine was the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(hydroxymethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine and its hydrochlorideIn the manner given in Example 25, 7-chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-chloroph enyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be refluxed to give 9-chloro-2-(hydroxymethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3- a][1,4]benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 2-(Hydroxymethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]ben zodiazepine and its hydrobromideIn the manner given in Example 25, 2-[[2-bromo-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-chlorophenyl)-3H-1 ,4-benzodiazepine in tetrahydrofuran can be refluxed to give 2-(hydroxymethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]be nzodiazepine as the hydrobromide. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(hydroxymethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine and its hydrochlorideIn the manner given in Example 25, 7-chloro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-fluoroph enyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be refluxed to give 9-chloro-2-(hydroxymethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3- a][1,4]benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Bromo-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a] [1,4]benzodiazepine and its hydrochloride.In the manner given in Example 24, 7-bromo-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1, 4-benzodiazepine in tetrahydrofuran can be stirred to give 9-bromo-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(trifluoromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]be nzodiazepine and its hydrobromideIn the manner given in Example 25, 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be treated with 3-bromo-1,1,1-trifluoropropanone and refluxed to give 9-chloro-2-(trifluoromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]b enzodiazepine as the hydrobromide. The free base can be obtained as described in Example 25.
PAC 9-Nitro-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzo diazepin and its hydrochloride.In the manner given in Example 25, 7-nitro-2-[[2-chloro-1-(hydroxymethyl)ethylidene]hydrazino]-5-phenyl-3H-1, 4-benzodiazepine in benzene can be refluxed to give 9-nitro-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Trifluoromethyl)-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a ][1,4]benzodiazepine and its hydrobromideIn the manner given in Example 24, 7-(trifluoromethyl)-2-[[2-bromo-1-(hydroxymethyl)ethylidene]hydrazino]-5-p henyl-3H-1,4-benzodiazepine in glyme can be stirred to give 9-(trifluoromethyl)-2-(hydroxymethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3 -a][1,4]benzodiazepine as the hydrobromide. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(2-hydroxyethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]ben zodiazepine and its hydrochlorideIn the manner given in Example 24, 7-chloro-2-[[2-chloro-1-(2-hydroxyethyl)ethylidene]hydrazino]-5-phenyl-3H- 1,4-benzodiazepine in diglyme can be stirred to give 9-chloro-2-(2-hydroxyethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]be nzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(3-chloropropyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3- a][1,4]benzodiazepine and its hydrochlorideIn the manner given in Example 24, 7-chloro-2-[[2-chloro-1-(3-chloropropyl)ethylidene]hydrazino]-5-(o-chlorop henyl)-3H-1,4-benzodiazepine in methanol can be stirred to give 9-chloro-2-(3-chloropropyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3 -a][1,4]benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Fluoro-2-(methoxymethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine and its hydrobromideIn the manner given in Example 24, 7-fluoro-2-[[2-bromo-1-(ethoxymethyl)ethylidene]hydrazino]-5-(o-fluorophen yl)-3H-1,4-benzodiazepine in toluene can be stirred to give 9-fluoro-2-(ethyoxymethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3- a][1,4]benzodiazepine as the hydrobromide. The free base can be obtained as described in Example 25.
PAC 9-Nitro-2-(2-carboethoxyethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4] benzodiazepine and its hydrochlorideIn the manner given in Example 25, 7-nitro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in glyme can be treated at 0° with ethyl 5-chlorolevulinate and then refluxed to give 9-nitro-2-(2-carbethoxyethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4] benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(fluoromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a] [1,4]benzodiazepine and its hydrochlorideIn the manner given in Example 24, 7-chloro-2-[[2-(chloro-1-(fluoromethyl)ethylidene]hydrazino]-5-(o-chloroph enyl)-3H-1,4-benzodiazepine in dioxane can be stirred to give 9-chloro-2-(fluoromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(3-carbomethoxypropyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1 ,4]benzodiazepine and its methansulfonateIn the manner given in Example 25, 7-chloro-2-[[2-hydroxy-1-(3-carbomethoxypropyl)ethylidene]hydrazino]-5-phe nyl-3H-1,4-benzodiazepine methanesulfonate in tetrahydrofuran can be refluxed to give 9-chloro-2-(3-carbomethoxypropyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][ 1,4]benzodiazepine as the methanesulfonate (salt). The free base can be obtained as described in Example 25.
PAC 9-Fluoro-2-(hydroxymethyl)-1-methyl-1,5-dihydro-7-phenyl-as-triazino[4,3-a] [1,4]benzodiazepine and its hydrochloride.In the manner given in Example 24, 7-fluoro-2-[[2-chloro-1-(hydroxymethyl)propylidene]hydrazino]-5-phenyl-3H- 1,4-benzodiazepine in tetrahydrofuran can be stirred to give 9-fluoro-2-(hydroxymethyl)-1-methyl-1,5-dihydro-7-phenyl-as-triazino[4,3-a ][1,4]benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-(Trifluoromethyl)-2-(2-chloroethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3- a][1,4]benzodiazepine and its hydrochlorideIn the manner given in Example 24, 7-(trifluoromethyl)-2-[[2-chloro-1-(2-chloroethyl)ethylidene] hydrazino]-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be stirred to give 9-(trifluoromethyl)-2-(2-bromoethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3- a][1,4]benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(3-hydroxypropyl)-1,5-dihydro-7-(2,6-difluorophenyl)-as-triazino [4,3-a][1,4]benzodiazepine and its hydrochlorideIn the manner given in Example 25, 7-chloro-2-[[2-chloro-1-(3-hydroxypropyl)ethylidene] hydrazino]-5-(2,6-difluorophenyl)-3H-1,4-benzodiazepine in tetrahydrofuran can be refluxed to give 9-chloro-2-(3-hydroxypropyl)-1,5-dihydro-7-(2,6-difluorophenyl)-as-triazin o[4,3-a][1,4]benzodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-(2-chloroethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine and its hydrochlorideIn the manner given in Example 24, 7-chloro-2-[[2-chloro-1-(2-chloroethyl)ethylidene]hydrazino]-5-phenyl-3H-1 ,4-benzodiazepine in tetrahydrofuran can be stirred to give 9-chloro-2-(2-chloroethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]ben zodiazepine as the hydrochloride. The free base can be obtained as described in Example 25.
PAC 9-Chloro-2-carbethoxy-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzodiaz epine, hydrobromideTo a solution of 2.85 g. (0.01 mole) of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 75 ml. of tetrahydrofuran under nitrogen was added 2.0 ml. (0.0257 mole) of ethyl bromopyruvate. The solution became dark and a solid soon separated. After standing for 5 days the solid was collected, washed with tetrahydrofuran and dried giving 2.07 g. of tan solid, melting point 205°-215°C (decomp). This solid was dissolved in 250 ml. of ethanol, treated at the boiling point with activated charcoal, filtered and concentrated until crystallization started (about 180 ml.). After standing overnight the crystals were collected, washed with ethanol and dried yielding 0.95 g. (20.3%) of 9-chloro-2-carbethoxy-1,5-dihydro-7-phenyl-as-triazino[ 4,3-a][1,4]benzodiazepine, hydrobromide of melting point 216°-223°C (decomp. with darkening from 205° up).
Anal. calcd. for C20 H18 BrClN4 O2 : C, 52.02; H, 3.93; Br, 17.31; Cl, 7.68; N, 12.13. Found: C, 51.93; H, 4.14; Br, 17.53; Cl, 7.07. (by difference from total halogen); N, 12.19.
PAC 9-Chloro-2-carboxy-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepi ne hydrochlorideIn the manner given in Example 47, 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in tetrahydrofuran can be stirred with chloropyruvic acid to give 9-chloro-2-carboxy-1,5-dihydro-7-phenyl-as-triazino-[4,3-a][1,4]benzodiaze pine as the hydrochloride.
PAC 9-Chloro-2-[(dimethylamino)methyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a][ 1,4]benzodiazepineTo a solution of 1.87 g. (0.005 mole) of 9-chloro-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a]-[1,4]ben zodiazepine hydrochloride in 250 ml. of methanol and 40 ml. of water was added, under nitrogen, with stirring 10 ml., (0.5 mole) of 20% aqueous dimethylamine. After stirring at room temperature for 5 hours the solution was evaporated in vacuo below 37°C The residue was dissolved in methylene chloride and washed with dilute aqueous sodium hydroxide, twice with water, and then with sodium chloride solution. After drying over anhydrous sodium sulfate and filtering, the methylene chloride solution was evaporated to dryness in vauco. The residue was dissolved in 25 ml. of 2-propanol, filtered, concentrated to 20 ml. and cooled giving 0.93 g. (59%) of 9-chloro-2-[(dimethylamino)methyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a] [1,4]benzodiazepine of melting point 169°-190°C with decomposition and darkening from 150° up.
Anal. calcd. for C20 H20 ClN5 : C, 65.66; H, 5.51; Cl, 9.69; N, 19.14. Found: C, 65.57; H, 5.65; Cl, 9.70; N, 18.83.
PAC 9-Chloro-7-(o-chlorophenyl)-2-[(dimethylamino)methyl]-1,5-dihydro-as-triazi no[4,3-a][1,4]benzodiazepineTo a solution of 0.856 g. (0.002 mole) of 9-chloro-2-(chloromethyl)-7-(o-chlorophenyl)-1,5-dihydro-as-triazino[4,3-a ][1,4]benzodiazepine hydrochloride in 100 ml. of methanol, under nitrogen, was added slowly with stirring 4 ml. (0.02 mole) of 2.5% aqueous dimethylamine. After stirring for 6 hours at room temperature and standing at 3°C overnight the solution was evaporated in vacuo below 35°C giving a light brown gum. This gum was dissolved in methylene chloride, washed with water, sodium chloride solution, and dried over anhydrous sodium sulfate. After filtration and evaporation of the solvent the product was triturated with ether, collected and dried yielding 0.6 g. of tan solid. This solid was dissolved in 700 ml. of ether at the boiling point, filtered, and concentrated to 50 ml. After cooling the product was collected, washed with ether and dried yielding 0.4 g. (50%) of yellow crystals of 9-chloro-7-(o-chlorophenyl)-2-[(dimethylamino)methyl]-1,5-dihydro-as-triaz ino[4,3-a][ 1,4]benzodiazepine of melting point 170°-174°C (decomp.).
Anal. calcd. for C20 H19 Cl2 N5 : C, 60.01; H, 4.78; Cl, 17.71; N, 17.50; Found: C, 59.97; H, 4.70; Cl, 17.33; N, 16.63.
PAC 2-(Methylaminomethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4 ]benzodiazepineIn the manner given in Example 49, 2-(chloromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]-be nzodiazepine can be reacted with aqueous methylamine to give 2-(methylaminomethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1, 4]benzodiazepine.
PAC 9-Chloro-2-(aminomethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a][ 1,4]benzodiazepineIn the manner given in Example 49, 9-chloro-2-(bromomethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino-[4,3-a ][1,4]benzodiazepine can be reacted with aqueous ammonia to give 9-chloro-2-(aminomethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a] [1,4]benzodiazepine.
PAC 9-Bromo-2-[(dimethylamino)methyl]-1,5-dihydro-7-(2-pyridyl)-as-triazino[4,3 -a][1,4]benzodiazepineIn the manner given in Example 49, 9-bromo-2-(chloromethyl)-1,5-dihydro-7-(2-pyridyl)-as-triazino[4,3-a][1,4] benzodiazepine can be reacted with aqueous dimethylamine to give 9-bromo-2-[(dimethylamino)methyl]-1,5-dihydro-7-(2-pyridyl)-as-triazino[4, 3-a][1,4]benzodiazepine.
PAC 9-Chloro-2-[(diethylamino)methyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1 ,4]benzodiazepineIn the manner given in Example 49, 9-chloro-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine can be reacted with diethylamine to give 9-chloro-2-[(diethylamino)methyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a][ 1,4]benzodiazepine.
PAC 9-Chloro-2-[(methylamino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as-triazino [4,3-a][1,4]benzodiazepineIn the manner given in Example 49, 9-chloro-2-(chloromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine can be reacted with aqueous monomethylamine to given 9-chloro-2-[(methylamino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as-triazin o[4,3-a][1,4]benzodiazepine.
PAC 9-Chloro-2-[2-(dimethylamino)ethyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a] [1,4]benzodiazepineIn the manner given in Example 49, 9-chloro-2-(2-bromoethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine can be reacted with aqueous dimethylamine to given 9-chloro-2-[2-(dimethylamino)ethyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a ][1,4]benzodiazepine.
PAC 9-Chloro-2-(pyrrolidinomethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4] benzodiazepineIn the manner given in Example 49, 9-chloro-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benz odiazepine can be reacted with pyrrolidine to give 9-chloro-2-(pyrrolidinomethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4 ]benzodiazepine.
PAC 9-(Trifluoromethyl)-2-(piperidinomethyl)-1,5-dihydro-7-phenyl-as-triazino[4 ,3-a][1,4]benzodiazepineIn the manner given in Example 49, 9-(trifluoromethyl)-2-(bromomethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a ][1,4]benzodiazepine can be reacted with piperidine to give 9-(trifluoromethyl)-2-(piperidinomethyl)-1,5-dihydro-7-phenyl-as-triazino[ 4,3-a][1,4]benzodiazepine.
PAC 9-Fluoro-2-[(4-methylpiperazino)methyl]-1,5-dihydro-7-(o-fluorophenyl)-as-t riazino[4,3-a][1,4]benzodiazepineIn the manner given in Example 49, 9-fluoro-2-(chloromethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine can be reacted with 4-methylpiperazine to give 9-fluoro-2-[(4-methylpiperazino)methyl]-1,5 -dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a][1,4]benzodiazepine.
PAC 9-Chloro-2-[[4-(2-hydroxyethyl)piperazino]methyl]-1,5-dihydro-7-(o-chloroph enyl)-as-triazino[4,3-a][1,4]benzodiazepineIn the manner given in Example 49, 9-chloro-2-(chloromethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a ][1,4]benzodiazepine can be reacted with 4-(2-hydroxyethyl)piperazine to give 9-chloro-2-[[4-(2-hydroxyethyl)piperazino]methyl]-1,5-dihydro-7-(o-chlorop henyl)-as-triazino[4,3-a][1,4]benzodiazepine.
PAC 9-(Trifluoromethyl)-2-[(methylethylamino)methyl]-1,5-dihydro-7-phenyl-as-tr iazino[4,3-a][1,4]benzodiazepineIn the manner given in Example 49, 9-(trifluoromethyl)-2-(chloromethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3- a][1,4]benzodiazepine can be reacted with methylethylamine to give 9-(trifluoromethyl)-2-[(methylethylamino)methyl]-1,5-dihydro-7-phenyl-as-t riazino[4,3-a][1,4]benzodiazepine.
PAC 9-Nitro-2-[(methylpropylamino)methyl]-1,5-dihydro-7-(o-fluorophenyl)-as-tri azino[4,3-a][1,4]benzodiazepineIn the manner given in Example 49, 9-nitro-2-(bromomethyl)-1,5-dihydro-7-(o-fluorophenyl)-as-triazino[4,3-a][ 1,4]benzodiazepine can be reacted with methylpropylamine to give 9-nitro-2-[(methylpropylamino)methyl]-1,5-dihydro-7-(o-fluorophenyl)-as-tr iazino[4,3-a][1,4]benzodiazepine.
PAC 9-Chloro-2-[(2-dimethylamino)ethyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a] [1,4]benzodiazepine(A) 9-Chloro-1,5-dihydro-2-methyl-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepi ne
A solution of 2.85 g. (0.01 mole) of 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine in 75 ml. of tetrahydrofuran, under nitrogen, was cooled to 0°C and 1 ml. (1.15 g., 0.0124 mole) of chloropropanone was added during 10 minutes with stirring. Stirring at 0°C is continued for 0.5 hours and then allowed to warm to room temperature and stirred for 2 hours. The mixture was then evaporated in vacuo at room temperature. The residue was dissolved in 150 ml. of warm ethyl acetate, filtered hot, concentrated to 50 ml. and cooled to give 2.93 g. (79%) of 7-chloro-2-[[(2-chloro-1-methyl)ethylidene]hydrazino]-5-phenyl-3H-1,4-benz odiazepine of melting point 210°-227°C (decomposition with darkening from 160°C up).
Anal. calcd. for C18 H16 Cl2 N4 : C, 60.18; H, 4.49; Cl, 19.74; N, 15.60. Found: C, 59.92; H, 4.53; Cl, 19.39; N, 15.49.
A solution of 0.72 g. (0.002 mole) of the hydrazone from A in 25 ml. of toluene, under nitrogen, was stirred under reflux for 4 hours. After standing overnight the resulting crystals were collected and washed with toluene and ether and dried, giving 0.32 g. of a brown solid. This solid was dissolved in 20 ml. of methanol, treated at the boiling point with decolorizing charcoal, filtered, concentrated by a stream of nitrogen on a steam bath to about 5 ml. and diluted with 2-propanol. Concentration was continued until crystallization started. After cooling, the product was collected, washed with 2-propanol and ether and dried to yield 0.2 g. (28%) of 9-chloro-1,5-dihydro-2-methyl-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepi ne hydrochloride of melting point 235°-245°C (decomposition with darkening from 213°C up).
Anal. calcd. for C18 H16 Cl2 N4 : C, 60.18; H, 4.49; Cl, 19.74; N, 15.60. Found: C, 60.08; H, 4.53; Cl, 19.58; N, 15.82.
The hydrochloride from above was mixed with dilute aqueous sodium hydroxide and extracted with chloroform. The chloroform extract was dried over magnesium sulfate, filtered and evaporated in vacuo to give 0.6 g. of brown crystalline solid. This was dissolved in chloroform, treated with decolorizing charcoal, filtered, concentrated and diluted with ether. After standing for 3 hours the product was collected, washed with ether and dried to give 0.35 g. (22%) of 9-chloro-1,5-dihydro-2-methyl-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepi ne. Melt solvate showed presence of chloroform of crystallization (0.0471 mole/mole) based on chlorine analysis.
Anal. calcd. for C18 H15 ClN4. 0.0471 CHCl3 C, 66.01; H, 4.62; Cl, 12,32; N, 17.06. Found: C, 65.94; H, 4.67; Cl, 12.32; N, 17.41.
A solution of 0.154 g. (0.0015 mole) of tetramethyldiaminomethane is dimethylformamide under nitrogen is cooled in an ice bath and 0.1 ml. of acetyl chloride is added slowly with stirring. To this slurry of dimethyl(methylene)ammonium chloride can be added 0.01 mole of 9-chloro-1,5-dihydro-2-methyl-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepi ne. The mixture can be stirred at room temperature until tlc (SiO2, 10% MeOH/CHCl3) indicates the reaction is complete. The product can be isolated as a hydrochloride by dilution of the reaction mixture with ether and filtration or alternatively the reaction mixture can be cooled, basified with sodium carbonate, extracted with chloroform and the free base chromatographed yielding 9-chloro-2-[(2-dimethylamino)ethyl]-1,5-dihydro-7-phenyl-as-triazino[4,3-a ][1,4]benzodiazepine.
PAC 9-Chloro-7-(o-chlorophenyl)-2-[(2-dimethylamino)ethyl]-1,5-dihydro-as-triaz ino[4,3-a][1,4]benzodiazepine(A) 9-Chloro-7-(o-chlorophenyl)-1,5-dihydro-2-methyl-as-triazino[4,3-a][1,4]be nzodiazepine hydrochloride
A mixture of 3.19 g. (0.01 mole) of 7-chloro-5-(o-chlorophenyl)-2-hydrazino-3H-1,4-benzodiazepine and 100 ml. of tetrahydrofuran under nitrogen was cooled to 0°C and 1 ml. of chloropropanone was slowly added with stirring. The mixture was allowed to warm to room temperature and after 1/2 hour, the solution was evaporated at room temperature in vacuo to given a light brown gum which was dissolved in absolute ether and filtered. The solution was concentrated on a steam bath to a small volume and pentane was added. After cooling in the refrigerator, the resulting crystals were collected, washed with ether and pentane and dried, yielding 3.82 g. (97%) of 7-chloro-2-[[(2-chloro-1-methyl)ethylidene]hydrazino]-5-(o-chlorophenyl)-3 H-1,4-benzodiazepine, melting point 202°-217° with decomposition and darkening from 120° up. A sample for analysis was recrystallized from isopropanol giving the same ir and melting behavior.
Anal. calcd. for C18 H15 Cl3 N4 : C, 54.91; H, 3.84; Cl, 27.01; N, 14.23. Found: C, 54.62; H, 4.13; Cl, 27.35; N, 14.23.
A soltuion of 3.15 g. (0.008 mole) of the hydrazone from above in 50 ml. of toluene, under nitrogen was stirred under reflux for 2.5 hours and allowed to stand for 3 days. The resulting solid was collected giving 1.78 g. of brown crystals. This was dissolved in 60 ml. of methanol, treated at the boiling point with decolorizing charcoal (Darco G-60), filtered, and concentrated to 15 ml. Dilution at boiling point to 50 ml. with absolute ether and cooling yielded 1.22 g. (38.8%) of 9-chloro-7-(o-chlorophenyl)-1,5-dihydro-2-methyl-as-triazino[4,3-a][1,4]be nzodiazepine hydrochloride, melting point 250°-260°C with decomposition from 225°C up.
Anal. calcd. for C18 H14 Cl2 N4 : C, 54.91; H, 3.84; Cl, 27.01; N, 14.23. Found: C, 54.75; H, 4.09; Cl, 26.94; N, 14.33.
The free base can be liberated from the hydrochloride by basifying with aqueous sodium carbonate, extracting with chloroform and evaporating the extract.
In the manner given in Example 63 a slurry of dimethyl(methylene)ammonium chloride in dimethylformamide can be treated with 9-chloro-7-(o-chlorophenyl)-1,5-dihydro-2-methyl-as-triazino[4,3-a][1,4]be nzodiazepine and stirred at room temperature to give 9-chloro-7-(o-chlorophenyl)-2-[(2-dimethylamino)ethyl]-1,5-dihydro-as-tria zino[4,3-a][1,4]benzodiazepine.
PAC 9-Chloro-2-(bromomethyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzod iazepineA mixture of 0.001 mole of 9-chloro-1,5-dihydro-2-methyl-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepi ne and 0.0011 mole of N-bromosuccinimide in carbon tetrachloride, under nitrogen, can be stirred under reflux until tlc indicates the reaction is complete. The product can be isolated by neutralization with aqueous sodium bicarbonate, extraction with methylene chloride and chromatographing on silica gel to give 9-chloro-2-bromomethyl-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzodi azepine.
PAC 9-Chloro-2-(bromomethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][ 1,4]benzodiazepineIn the manner given in Example 65, 9-chloro-1,5-dihydro-2-methyl-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]be nzodiazepine can be mixed with N-bromosuccinimide and carbon tetrachloride and stirred under reflux to give 9-chloro-2-(bromomethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a] [1,4]benzodiazepine.
In the manner given in Example 1, other 2-[[2-halo-1-substituted ethylidene]hydrazino]-5 -phenyl-3H-1,4-benzodiazepines can be obtained. Representative compounds thus obtained include:
7-chloro-2-[[2-chloro-1-carboxyethylidene]hydrazino]-5-phenyl-3H- 1,4-benzodiazepine;
8-fluoro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-(o-chlorophen yl)-3H-1,4-benzodiazepine;
7-nitro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-(o-chloropheny l)-3H-1,4-benzodiazepine;
7-nitro-2-[[2-bromo-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-chloropheny l)-3H-1,4-benzodiazepine;
6-nitro-2-[[2-bromo-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-chloropheny l)-3H-1,4-benzodiazepine;
9-trifluoromethyl-2-[[2-bromo-(hydroxymethyl)ethylidene]hydrazino]-5-(o-flu orophenyl)-3H-1,4-benzodiazepine;
7-trifluoromethyl-2-[[2-chloro-1-(chloroethyl)ethylidene]hydrazino]-5-(o-ch lorophenyl)-3H-1,4-benzodiazepine;
7-fluoro-2-[[2-chloro-1-(chloromethyl)ethylidene]hydrazino]-5-(2,6-difluoro phenyl)-3H-1,4-benzodiazepine;
8-fluoro-2-[[2 -chloro-1-(carboxyethyl)ethylidene]hydrazino]-5-(o-chlorophenyl)-3H-1,4-be nzodiazepine;
9-fluoro-2-[[2-bromo-1-(carboxypropyl)ethylidene]hydrazino]-5-phenyl-3H-1,4 -benzodiazepine;
7-bromo-2-[[2-chloro-1-(2-hydroxy-2-methylpropyl)ethylidene]hydrazino]-5-ph enyl-3H-1,4-benzodiazepine;
8-bromo-2-[[2-bromo-1-(hydroxymethylpropylidene)]hydrazino]-5-(2,6-difluoro phenyl)-3H-1,4-benzodiazepine;
2-[[2-chloro-1-(3-carbomethoxypropyl)ethylidene]hydrazino]-5-(o-chloropheny l)-3H-1,4-benzodiazepine;
2-[[2-bromo-1-(hydroxymethyl)ethylidene]hydrazino]-5-(o-chlorophenyl)-3H-1, 4-benzodiazepine;
2-[[2-chloro-1-carboxyethylidene]hydrazino]-5-(o-chlorophenyl)-3H-1,4-benzo diazepine;
7-fluoro-2-[[2-chloro-1-carboxyethylidene]hydrazino]-5-(o-chlorophenyl)-3H- 1,4-benzodiazepine;
and the like.
In the manner given in Example 24, other 2-substituted-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepines can be prepared. Representative compounds, thus obtained, include:
10-fluoro-2-chloromethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][ 1,4]benzodiazepine;
9-nitro-2-chloromethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1, 4]benzodiazepine;
9-nitro-2-hydroxymethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1 ,4]benzodiazepine;
8-nitro-2-hydroxymethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1 ,4]benzodiazepine;
11-trifluoromethyl-2-hydroxymethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazi no[4,3-a][1,4]benzodiazepine;
9-trifluoromethyl-2-chloroethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[ 4,3-a][1,4]benzodiazepine;
9-fluoro-2-chloromethyl-1,5-dihydro-7-(2,6-difluorophenyl)-as-triazino[4,3- a][1,4]benzodiazepine;
10-fluoro-2-carboxyethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][ 1,4]benzodiazepine;
11-fluoro-2-carboxypropyl-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzo diazepine;
9-bromo-2-(2-hydroxy-2-methylpropyl)-1,5-dihydro-7-phenyl-as-triazino[4,3-a ][1,4]benzodiazepine;
10-bromo-2-(2-hydroxyethyl)-1,5-dihydro-7-(2,6-difluorophenyl)-as-triazino[ 4,3-a][1,4]benzodiazepine;
2-(3-carbomethoxypropyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][ 1,4]benzodiazepine;
2-hydroxymethyl-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]benzo diazepine;
2-carboxy-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]benzodiazep ine;
8-fluoro-2-carboxy-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4,3-a][1,4]be nzodiazepine;
and the like.
In the manner given in Example 49, 2-aminoalkyl-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepines can be synthesized from the corresponding 2-chloroalkyl-1,5-dihydro-7-phenyl-as-triazino[4,3-a][1,4]benzodiazepine and a secondary amine. Representative compounds, thus produced, include:
10-fluoro-2-[(dimethylamino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as-triaz ino[4,3-a][1,4]benzodiazepine;
10-fluoro-2-[(diethylamino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as-triazi no[4,3-a][1,4]benzodiazepine;
10-fluoro-2-(pyrrolidinomethyl)-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[ 4,3-a][1,4]benzodiazepine;
10-fluoro-2-[(4-methylpiperazino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as- triazino[4,3-a][1,4]benzodiazepine;
9-nitro-2-[(dimethylamino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as-triazin o[4,3-a][1,4]benzodiazepine;
9-nitro-2-[[4-[(2-hydroxyethyl)piperazino]methyl]-1,5-dihydro-(o-chlorophen yl)-as-triazino[4,3-a][1,4]benzodiazepine;
9-nitro-2-[(piperidino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4 ,3-a][1,4]benzodiazepine;
9-nitro-2-[(morpholino)methyl]-1,5-dihydro-7-(o-chlorophenyl)-as-triazino[4 ,3-a][1,4]benzodiazepine;
9-trifluoromethyl-2-[2-[(diethylamino)ethyl]]-1,5-dihydro-7-(o-chlorophenyl )-as-triazino[4,3-a][1,4]benzodiazepine;
9-trifluoromethyl-2-[2-(morpholino)ethyl]-1,5-dihydro-7-(o-chlorophenyl)-as -triazino[4,3-a][1,4]benzodiazepine;
9-trifluoromethyl-2-[2-(piperidino)ethyl]-1,5-dihydro-7-(o-chlorophenyl)-as -triazino[4,3-a][1,4]benzodiazepine;
9-trifluoromethyl-2-[2-(dipropylamino)ethyl]-1,5-dihydro-7-(o-chlorophenyl) -as-triazino[4,3-a][1,4]benzodiazepine;
9-fluoro-2-[di(isopropylamino)methyl]-1,5-dihydro-7-(2,6-difluorophenyl)-as -triazino[4,3-a][1,4]benzodiazepine;
2-[(diethylamino)methyl]-1,5-dihydro-7-(2,6-difluorophenyl)-as-triazino[4,3 -a][1,4]benzodiazepine;
2-[[4-(2-hydroxyethyl)piperazino]methyl]-1,5-dihydro-7-(2,6-difluorophenyl) -as-triazino[4,3-a][1,4]benzodiazepine;
2-[(4-methylpiperazino)methyl]-1,5-dihydro-7-(2,6-difluorophenyl)-as-triazi no[4,3-a][1,4]benzodiazepine; and the like.
The pharmacologically acceptable acid addition salts of compounds of formula IV can be prepared and isolated by conventional processes, such as reacting a compound of formula IV with a selected pharmacologically acceptable acid. Such acids include hydrochloric, hydrobromic, phosphoric, sulfuric, acetic, tartaric, lactic, citric, malic, maleic, methanesulfonic, benzenesulfonic, cyclohexanesulfamic acids, toluenesulfonic, and the like. The reaction is conveniently performed in an organic solvent, e.g., ether, dioxane, or tetrahydrofuran, ethanol, methanol, ethyl acetate; the salts can be recovered by crystallization, precipitation or evaporating the solvent. These salts are useful in the same manner as the free base.
Patent | Priority | Assignee | Title |
4073784, | Mar 09 1977 | The Upjohn Company | Certain as-triazino 4,3-a! 1,4!benzodiazepine-1,2-dione compounds |
4073785, | Mar 09 1977 | The Upjohn Company | Certain as-triazino 4,3-a! 1,4!benzodiazepine derivatives |
4086230, | Mar 09 1977 | The Upjohn Company | 1,5-Dihydro-7-aryl-as-triazine[4,3,-α][1,4]benzodiazepin-1-ols |
Patent | Priority | Assignee | Title |
3818003, | |||
3933816, | Sep 12 1974 | The Upjohn Company | 3-(Substituted aminomethyl)-7-substituted-3,5-dihydro-as-triazino[4,3-a][1,5]benzodiaze pines |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Feb 09 1976 | The Upjohn Company | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Date | Maintenance Schedule |
Jun 07 1980 | 4 years fee payment window open |
Dec 07 1980 | 6 months grace period start (w surcharge) |
Jun 07 1981 | patent expiry (for year 4) |
Jun 07 1983 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jun 07 1984 | 8 years fee payment window open |
Dec 07 1984 | 6 months grace period start (w surcharge) |
Jun 07 1985 | patent expiry (for year 8) |
Jun 07 1987 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jun 07 1988 | 12 years fee payment window open |
Dec 07 1988 | 6 months grace period start (w surcharge) |
Jun 07 1989 | patent expiry (for year 12) |
Jun 07 1991 | 2 years to revive unintentionally abandoned end. (for year 12) |